The hallmark of chronic myelogenous leukemia (CML) is the presence of the BCR-ABL fusion gene associated with the Philadelphia chromosome (Ph). All cases of CML have a t(9;22) or variant and detection of this genetic abnormality is important in the diagnosis of CML. The BCR/ABL fusion gene resulting from the t(9;22) is the target for the tyrosine kinase inhibitor drug imatinib.
CPT Code(s): 88374 (reference only; CPTs may vary)
Turnaround Time: Within 3-4 business days of receipt
Schedule: Monday - Friday
• Peripheral blood, Preferred: 3 ml in sodium heparin (green top) / Acceptable: 3 ml in EDTA (purple top) - OR -
• Bone marrow aspirate, Preferred: 1-2 ml in sodium heparin (green top) / Acceptable: 1-2 ml in EDTA (purple top) - OR -
• Fresh tissue in RPMI - OR -
• Formalin-fixed, paraffin-embedded tissue (FFPE)